Asia Rainbow Medicine: APL-1702 marketing authorization application accepted by the European Medicines Agency.

Yahong Pharmaceuticals announced that it has received notification from the European Medicines Agency that the marketing authorization application for its product APL-1702 for the treatment of patients with high-grade cervical intraepithelial neoplasia has been accepted. After the marketing authorization application is accepted, the product still needs to go through subsequent evaluation and approval processes, and there is uncertainty about whether it will successfully launch and the specific timing of the launch. Even if it is approved, there is still uncertainty about whether it will achieve its commercial goals. The acceptance of the marketing authorization application for the above-mentioned product will not have a significant impact on the company's recent performance.